Mellinghoff, Ingo K.

Publications

Sort by

Co-Author Network

selected publications

Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors. Acta neuropathologica communications. 2024 Academic Article GET IT
Multiplexed Spatial Profiling of Hodgkin Reed-Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
A Phase II study assessing Long-Term Response to Ibrutinib Monotherapy in recurrent or refractory CNS Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma. JCO oncology practice. 2024 Academic Article GET IT
State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2024 Review GET IT
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Editorial Article GET IT
Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas. Acta neuropathologica. 2023 Academic Article GET IT
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1. Neuro-oncology. 2023 Academic Article GET IT
A Review of Glioblastoma and Other Primary Brain Malignancies-Reply. JAMA. 2023 Letter GET IT
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. 2023 GET IT
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma. Leukemia & lymphoma. 2023 Academic Article GET IT
Times cited: 4
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. The New England journal of medicine. 2023 Academic Article GET IT
Times cited: 11
Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology. Cancer discovery. 2023 Academic Article GET IT
Times cited: 3
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nature medicine. 2023 Academic Article GET IT
Times cited: 80
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023 Review GET IT
Times cited: 29
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers. Nature communications. 2023 Academic Article GET IT
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-oncology. 2023 Academic Article GET IT
Times cited: 85
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-oncology. 2022 Academic Article GET IT
Times cited: 233
Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case Series. Neurology. 2022 Academic Article GET IT
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-oncology. 2022 Academic Article GET IT
Times cited: 12
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-oncology. 2022 Academic Article GET IT
Times cited: 54
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. Neuro-oncology. 2022 Academic Article GET IT
Times cited: 29
Noninvasive Imaging of CD4+ T Cells in Humanized Mice. Molecular cancer therapeutics. 2022 Academic Article GET IT
Times cited: 4
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. NPJ breast cancer. 2022 Academic Article GET IT
Times cited: 13
Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer immunology research. 2022 Academic Article GET IT
Times cited: 4
Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Review GET IT
Times cited: 11
Next-generation Sequencing of Cerebrospinal Fluid for Clinical Molecular Diagnostics in Pediatric, Adolescent and Young Adult (AYA) Brain Tumor Patients. Neuro-oncology. 2022 Academic Article GET IT
Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. BMC cancer. 2022 Academic Article GET IT
Times cited: 8
GCN2 kinase activation by ATP-competitive kinase inhibitors. Nature chemical biology. 2021 Academic Article GET IT
Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. Hematology/oncology clinics of North America. 2021 Review GET IT
Times cited: 6
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 146
Prognostic value of [¹⁸F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. European journal of nuclear medicine and molecular imaging. 2021 Academic Article GET IT
Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. The Journal of molecular diagnostics : JMD. 2021 Academic Article GET IT
Times cited: 24
Meningeal lymphatics prime tumor immunity in glioblastoma. Cancer cell. 2021 Comment GET IT
Times cited: 22
OncoTree: A Cancer Classification System for Precision Oncology. JCO clinical cancer informatics. 2021 Academic Article GET IT
Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [⁶⁴Cu]Cu-NOTA-anti-CD8 PET. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 28
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro-oncology. 2020 Academic Article GET IT
Times cited: 24
Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. Acta neuropathologica communications. 2020 Academic Article GET IT
Times cited: 31
Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy. International journal of molecular sciences. 2020 Review GET IT
Times cited: 15
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-oncology. 2020 Review GET IT
Times cited: 655
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 193
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. Annals of clinical and translational neurology. 2020 Academic Article GET IT
Times cited: 36
Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2020 Review GET IT
Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas. Brain pathology (Zurich, Switzerland). 2020 Academic Article GET IT
Times cited: 3
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS medicinal chemistry letters. 2020 Academic Article GET IT
Times cited: 121
Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. Oncotarget. 2019 Academic Article GET IT
Times cited: 15
Pharmacokinetic Assessment of ¹⁸F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 21
Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. Nature reviews. Clinical oncology. 2019 Article GET IT
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. Journal of neuro-oncology. 2019 Academic Article GET IT
Times cited: 45
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 113
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Investigational new drugs. 2019 Academic Article GET IT
Times cited: 69
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature medicine. 2019 Academic Article GET IT
Times cited: 959
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 113
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019 Academic Article GET IT
Times cited: 390
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2018 Academic Article GET IT
Times cited: 184
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-oncology. 2018 Academic Article GET IT
Times cited: 65
Metabolic Imaging of the Human Brain with Hyperpolarized ¹³C Pyruvate Demonstrates ¹³C Lactate Production in Brain Tumor Patients. Cancer research. 2018 Academic Article GET IT
Times cited: 181
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 37
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸F-(2S,4R)-4-Fluoroglutamine. Radiology. 2018 Academic Article GET IT
Times cited: 84
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nature communications. 2017 Academic Article GET IT
Times cited: 20
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 55
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. Journal of neuro-oncology. 2017 Academic Article GET IT
Times cited: 23
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer discovery. 2017 Academic Article GET IT
Times cited: 313
Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Molecular systems biology. 2017 Academic Article GET IT
Times cited: 56
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 297
Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI insight. 2016 Academic Article GET IT
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Information Resource GET IT
Times cited: 13
MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell reports. 2016 Academic Article GET IT
Times cited: 174
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-oncology. 2015 Academic Article GET IT
Times cited: 157
Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization. Bioorganic & medicinal chemistry. 2015 Academic Article GET IT
Times cited: 28
T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status. AJNR. American journal of neuroradiology. 2015 Academic Article GET IT
Times cited: 50
PI3K pathway inhibition in GBM—is there a signal?. Neuro-oncology. 2015 Editorial Article GET IT
Times cited: 7
Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-oncology. 2015 Information Resource GET IT
Times cited: 176
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science translational medicine. 2015 Academic Article GET IT
Times cited: 252
IQGAP1 controls tight junction formation through differential regulation of claudin recruitment. Journal of cell science. 2015 Academic Article GET IT
Times cited: 24
Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer discovery. 2015 Academic Article GET IT
Times cited: 114
A kinase-independent function of AKT promotes cancer cell survival. eLife. 2014 Academic Article GET IT
Times cited: 65
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro-oncology. 2014 Information Resource GET IT
Times cited: 91
A correlative optical microscopy and scanning electron microscopy approach to locating nanoparticles in brain tumors. Micron (Oxford, England : 1993). 2014 Academic Article GET IT
Times cited: 26
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro-oncology. 2014 Review GET IT
Times cited: 27
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 88
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell reports. 2014 Academic Article GET IT
Times cited: 100
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell metabolism. 2013 Academic Article GET IT
Times cited: 343
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 953
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature genetics. 2013 Academic Article GET IT
Times cited: 283
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-oncology. 2012 Academic Article GET IT
Times cited: 90
Imaging tumor burden in the brain with 89Zr-transferrin. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012 Academic Article GET IT
Times cited: 37
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Science signaling. 2012 Academic Article GET IT
Times cited: 48
Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 62
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Molecular systems biology. 2012 Academic Article GET IT
Times cited: 167
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nature medicine. 2012 Academic Article GET IT
Times cited: 947
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer discovery. 2012 Academic Article GET IT
Times cited: 279
IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 102
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Academic Article GET IT
Times cited: 1616
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012 Academic Article GET IT
Times cited: 1567
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS computational biology. 2012 Academic Article GET IT
Times cited: 55
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 86
Virchow 2011 or how to ID(H) human glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 13
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer discovery. 2011 Academic Article GET IT
Times cited: 323
18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer research. 2011 Academic Article GET IT
Times cited: 106
Epidermal growth factor receptor inhibitors in oncology. Current opinion in oncology. 2010 Information Resource GET IT
Times cited: 43
Tracing cancer networks with phosphoproteomics. Nature biotechnology. 2010 Article GET IT
Times cited: 14
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 98
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 97
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science signaling. 2009 Academic Article GET IT
Times cited: 284
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature genetics. 2009 Academic Article GET IT
Times cited: 334
Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. The Journal of general virology. 2009 Academic Article GET IT
Times cited: 39
PTEN dosage is essential for neurofibroma development and malignant transformation. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 96
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. The Journal of clinical investigation. 2009 Academic Article GET IT
Times cited: 356
14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell cycle (Georgetown, Tex.). 2009 Academic Article GET IT
Times cited: 6
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer cell. 2009 Academic Article GET IT
Times cited: 119
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 232
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nature biotechnology. 2008 Academic Article GET IT
Times cited: 206
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine. 2008 Academic Article GET IT
Times cited: 495
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 76
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 869
Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?. PLoS medicine. 2007 Information Resource GET IT
Times cited: 5
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer cell. 2007 Academic Article GET IT
Times cited: 192
Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 85
High-throughput oncogene mutation profiling in human cancer. Nature genetics. 2007 Academic Article GET IT
Times cited: 835
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS medicine. 2006 Academic Article GET IT
Times cited: 293
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer research. 2006 Academic Article GET IT
Times cited: 203
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS computational biology. 2006 Academic Article GET IT
Times cited: 129
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 141
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature medicine. 2005 Academic Article GET IT
Times cited: 513
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England journal of medicine. 2005 Academic Article GET IT
Times cited: 1178
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2005 Academic Article GET IT
Times cited: 96
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer cell. 2004 Academic Article GET IT
Times cited: 274
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. The Journal of biological chemistry. 2003 Academic Article GET IT
Times cited: 296
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer research. 2002 Academic Article GET IT
Times cited: 81
The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics. 2002 Information Resource GET IT
Times cited: 22
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 923
Buerger disease or arsenic intoxication?. Archives of internal medicine. 2001 Article GET IT
The role of cocaine in the etiology of Buerger disease is questionable. Archives of internal medicine. 2001 Article GET IT
Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology. 1991 Academic Article GET IT
Times cited: 39
Effect of genistein, a tyrosine kinase inhibitor, on latent EBV activation induced by cross-linkage of membrane IgG in Akata B cells. Journal of immunology (Baltimore, Md. : 1950). 1991 Academic Article GET IT
Times cited: 22

more ...

less ...

Background

education and training

M.D., Technical University of Munich, Faculty of Medicine (Germany) 1993

Contact

full name

Ingo K. Mellinghoff

primary email

mellingi@mskcc.org

VIVO Weill Cornell Medical College

Ingo K. Mellinghoff Professor of Neurology

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email